Hayano S, Tanaka A
Infect Immun. 1977 Jan;15(1):300-4. doi: 10.1128/iai.15.1.300-304.1977.
Repetitive counterelectrophoresis (RCE), which has been described (Hayano and Tanaka, 1977), was used to assay the contents of antibodies to streptococcal esterases (STE) in sera from patients with scarlet fever. The levels of antibodies to STE were expressed semiquantitatively by reading the intensity of the colored spot developed by RCE with a densitometer. The present study deals with the determination of anti-STE in sera drawn at intervals from 54 patients diagnosed as suffering from scarlet fever. The STE used in this study were prepared from the streptococcal strains as follows. STE-AI was prepared from SS379 (group A, type 40), STE-AII from strain 69882 (group A, type 49), STE-B from strain H36B (group B, lb), and STE-C from strain Austin (group C). Of the 54 cases studied, 32 (59.3%) showed anti-STE-AI, 24 (44.4%) showed anti-STE-AII, 5 (9.3%) showed anti-STE-B, and 23 (42.6%) showed anti-STE-C. Comparison of the titer of anti-streptolysin O (ASLO) with the type of specific reaction of anti-STE-AI and -AII, determined in the same specimen, showed a marked correlation. Of 20 cases giving ASLO titers of 12 or less, 18 showed no sign of anti-STE-AI and -AII and two showed signs of anti-STE-AI. Of 34 cases giving ASLO titers of more than 12, 33 showed signs of anti-STE-AI and/or -AII, 22 showed signs of anti-STE-AI and -AII, 7 showed signs of anti-STE-AI, and 4 showed signs of anti-STE-AII. Of all the cases, 26 showed coincident rises in titers of ASLO and levels of anti-STE-AI and/or -AII during the course of the disease. One case showed the presence of only anti-STE-B. All of the 23 cases that showed the presence of anti-STE-C showed signs of anti-STE-AI. Some of these cases showed a marked increase in levels of anti-STE-C during the course of the disease.
重复对流免疫电泳(RCE)(Hayano和Tanaka,1977年已对此进行过描述)被用于检测猩红热患者血清中抗链球菌酯酶(STE)抗体的含量。通过用密度计读取RCE显色斑点的强度,对抗STE抗体水平进行半定量表达。本研究涉及对54例确诊为猩红热的患者在不同时间抽取的血清中抗STE的测定。本研究中使用的STE是由以下链球菌菌株制备的。STE-AI由SS379(A组,40型)制备,STE-AII由69882菌株(A组,49型)制备,STE-B由H36B菌株(B组,1b型)制备,STE-C由Austin菌株(C组)制备。在研究的54例病例中,32例(59.3%)显示有抗STE-AI,24例(44.4%)显示有抗STE-AII,5例(9.3%)显示有抗STE-B,23例(42.6%)显示有抗STE-C。在同一标本中测定的抗链球菌溶血素O(ASLO)滴度与抗STE-AI和-AII的特异性反应类型的比较显示出明显的相关性。在20例ASLO滴度为12或更低的病例中,18例未显示抗STE-AI和-AII的迹象,2例显示有抗STE-AI的迹象。在34例ASLO滴度高于12的病例中,33例显示有抗STE-AI和/或-AII的迹象,22例显示有抗STE-AI和-AII的迹象,7例显示有抗STE-AI的迹象,4例显示有抗STE-AII的迹象。在所有病例中,26例在疾病过程中ASLO滴度和抗STE-AI和/或-AII水平同时升高。1例仅显示有抗STE-B。显示有抗STE-C的23例病例均显示有抗STE-AI的迹象。其中一些病例在疾病过程中抗STE-C水平显著升高。